BioSpace Insights
The BioSpace Insights team performs research and analysis on industry trends for BioSpace and clients, producing industry reports, podcasts, events and articles.
Latest from Insights
As with any new year, 2024 presents new possibilities; though new and existing challenges are also poised to shape its trajectory. BioSpace reflects on the recent JP Morgan Healthcare Conference and future outlook with key opinion leaders who share their thoughts on the economic climate.
Surviving and Thriving in the Never-ending Biotech Downturn
LIVE WEBINAR | MAY 20 | 2PM–3PM EST
The rumors of biotech’s return have been greatly exaggerated. Despite some M&A sparks, a handful of mega fundraises and a trickle of IPOs, the biotech industry continues to climb out of a multi-year down period. So how does a company thrive in this environment?
BioSpace sits down with four NextGen companies doing just that, to hear about ways they are defying the odds to churn out clinical data that may finally provide the industry with a ladder out.
LIVE WEBINAR | MAY 20 | 2PM–3PM EST
The rumors of biotech’s return have been greatly exaggerated. Despite some M&A sparks, a handful of mega fundraises and a trickle of IPOs, the biotech industry continues to climb out of a multi-year down period. So how does a company thrive in this environment?
BioSpace sits down with four NextGen companies doing just that, to hear about ways they are defying the odds to churn out clinical data that may finally provide the industry with a ladder out.
LIVE WEBINAR | JUNE 25 | 11AM - 12PM EST
Are long R&D cycles, overwhelming literature reviews, or patent bottlenecks slowing your path to innovation? In the fast-evolving life science landscape, AI is no longer a luxury—it’s a necessity. Join our exclusive webinar to discover how cutting-edge AI tools empower R&D teams, IP strategists, and innovation leaders.
Are long R&D cycles, overwhelming literature reviews, or patent bottlenecks slowing your path to innovation? In the fast-evolving life science landscape, AI is no longer a luxury—it’s a necessity. Join our exclusive webinar to discover how cutting-edge AI tools empower R&D teams, IP strategists, and innovation leaders.
Listen to Denatured
Unravel the business of science with BioSpace.
In this episode of Denatured, BioSpace’s Head of Insights Lori Ellis, Miguel Forte and Ali Pashazadeh discuss the industry’s need to catch up with women’s health issues and the innovative lead the APAC region has taken in clinical trials.
In this episode of Denatured, BioSpace’s Head of Insights Lori Ellis, Miguel Forte and Ali Pashazadeh speculate on the impending Trump administration, discuss current challenges faced by CEOs and weigh investment in GLP-1s.
In this episode of Denatured, BioSpace’s Head of Insights Lori Ellis, Miguel Forte and Ali Pashazadeh discuss how a slow and steady pace is a continuation of the pattern we have seen throughout the last three years.
Webinars
This webinar explores the pivotal role of patent data in overcoming the data challenges faced by generative AI models in drug discovery, particularly for biologics. Watch now.
BioSpace at 2025 SCOPE Summit
Events
In this live panel discussion, speakers focused on the EU AI Act’s global regulatory implications for medical devices & QARA’s future. An executive summary is available.
- BIO International Convention: June 16-19, 2025 | Boston, MA
- Bioprocessing Summit: August 18-21, 2025 | Boston, MA
- Meeting on the Mesa: October 6-8, 2025 | Phoenix, AZ
BioSpace x DIA
The groundwork being done in 2024 is building the foundation for global collaboration in the future.
DRUG DEVELOPMENT
DRUG DEVELOPMENT
FROM BIOSPACE INSIGHTS
In this episode, Lori and guests discuss the pursuit of adequate representation and how clinical trials are being shaped by the legal environment they operate within.
This is the third episode of Denatured’s discussion on diversity, equity and inclusion. Here, our guests discuss imperatives around access and accountability.
This week on Denatured, Head of Insights Lori Ellis and guests discuss the implications of not addressing the DE&I data gaps for the future.
Expansion across its network will mean hundreds of new employees in Cincinnati, increased ability to get complex medicines to patients and more.
This week on Denatured, Head of Insights Lori Ellis and guests discuss the persisting challenges of diversity, equity and inclusion when designing clinical trials.
BioSpace’s third report on diversity, equity, inclusion and belonging in life sciences examines dramatic shifts in attitude around diversity initiatives.
In the second episode of our series on women’s health, we discuss what may happen to future generations if women, the custodians of generational health, are not comfortable sharing complete medical histories.
Takeda Oncology US Head of Sales, Annette Montandon, discusses how embodying a patient-first approach is key to the success of colorectal cancer drug FRUZAQLA®.
Federal funding and legislation spotlight women’s health opportunities and challenges.
The pharmaceutical industry is facing critical attention, particularly around drug pricing and development costs. Drug development cost is about 10% of the total healthcare spend in the United States. Broader issues such as local monopolies, utilization, unit, and costs and local monopolies, politics and a fragmented payer system contribute to the increasingly high costs to patients.